Wyden Statement on Trump Announcement on Obesity Drugs

Wyden Statement on Trump Announcement on Obesity Drugs

As Trump Continues Parading Pharmaceutical Executives Through the Oval Office, Americans Are Left Scratching Their Heads About When Their Costs Will Go Down

Washington, D.C. - Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued a statement ahead of a planned announcement by Donald Trump at the White House, joined by pharmaceutical executives from Eli Lilly and Novo Nordisk.

"The announcement of a lower price for Ozempic and other anti-obesity drugs is made possible by Medicare negotiation, which Democrats passed with no Republican support," Wyden said. "Medicare negotiated lower prices weeks ago, and rather than share those prices, Trump is too busy hosting CEOs from Big Pharma at the White House with fake announcements that juice their stock prices. It's also important to keep in mind that one of Robert Kennedy's first actions in office was to revoke a plan to allow Medicare to cover these drugs. As always, there are many reasons to be skeptical that Trump's announcement is more smoke and mirrors that won't result in lower prices for American families, while big corporations pop champagne in the board room."

###